Basics Ardelyx, Inc. Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. IPO Date: June 19, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.42B Activated in VL: True Average Daily Range Avg Daily Range: $0.23 | 3.22% Avg Daily Range (30 D): $0.13 | 2.37% Avg Daily Range (90 D): $0.11 | 1.97% Institutional Daily Volume Avg Daily Volume: 2.4M Avg Daily Volume (30 D): 3.49M Avg Daily Volume (90 D): 3.32M Trade Size Avg Trade Size (Sh.): 262 Avg Trade Size (Sh.) (30 D): 160 Avg Trade Size (Sh.) (90 D): 167 Institutional Trades Total Inst.Trades: 1,520 Avg Inst. Trade: $2.2M Avg Inst. Trade (30 D): $1.93M Avg Inst. Trade (90 D): $1.89M Avg Inst. Trade Volume: .43M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.9M Avg Closing Trade (30 D): $2.14M Avg Closing Trade (90 D): $2.2M Avg Closing Volume: 544.36K     News Jun 2, 2025 @ 5:50 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A May 21, 2025 @ 12:00 PM Ardelyx to Participate at the Jefferies Global Hea... Source: N/A Apr 24, 2025 @ 12:01 PM Ardelyx Announces Three Abstracts Accepted for Pos... Source: N/A Feb 19, 2025 @ 1:01 PM Ardelyx to Present at the TD Cowen 45th Annual Hea... Source: Ardelyx, Inc. Jan 6, 2025 @ 1:00 PM Ardelyx to Present at the 43rd Annual J.P. Morgan ... Source: N/A Financials   TTM Q3 2025 Q2 2025 Basic EPS $-.23 $ $-.08 Diluted EPS $-.23 $ $-.08 Revenue $ 398.23M $ 110.33M $ 97.66M Gross Profit $ 351.28M $ 106.35M $ 85.26M Net Income / Loss $ -56.55M $ -.97M $ -19.08M Operating Income / Loss $ -37.95M $ 4.67M $ -14.4M Cost of Revenue $ 46.95M $ 3.98M $ 12.4M Net Cash Flow $ -4.71M $ -47.33M $ 59.24M PE Ratio